Taken together, CD8+MAIT cells are enriched in responders-derived peripheral blood, and these cytotoxic CD8+MAIT cells may increase the sensitivity of patients with NSCLC to anti-PD-1 therapy by promoting the expression of corresponding cytotoxic molecules, thereby leading to a better prognosis. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.